1. Introduction: The Evolution of Wound Bed Preparation (WBP)
As senior specialists and nurse educators, we have seen Wound Bed Preparation (WBP) evolve from simple topical care into a sophisticated, evidence-based paradigm. The 2021 WBP model emphasizes a holistic approach: treating the cause and addressing patient-centered concerns before deciding on a local care strategy. While our foundational work—cleansing, debridement, and moisture balance—is essential, we must recognize the specific clinical moment to transition to “active therapies.”
According to Statement 9 of the 2021 paradigm, we introduce advanced biologics when we encounter the “Edge Effect.” This occurs in healable wounds that have stalled despite four weeks of optimal standard care. When the wound edge fails to migrate, we must look beyond the basics to jump-start the healing trajectory.
2. The Clinical Prerequisite: Is the Wound Ready?
Before we advocate for the use of high-cost growth factors or skin substitutes, we must ensure the wound bed is physiologically prepared. As educators, we must teach our teams that applying these products to an unprepared bed is a waste of clinical resources.
Prerequisites for Advanced Therapy:
- Vascular Supply: We must confirm adequate perfusion. An Audible Handheld Doppler (AHHD) is our reliable bedside tool. We look for triphasic or biphasic signals; a palpable pulse typically indicates a pressure of >80 mm Hg.
- Clinical Alert: If you hear a monophasic or absent signal, this is an immediate trigger for an urgent referral for duplex studies and vascular intervention (Statement 1A).
- Healability Status: The wound must be classified as “Healable” (Statement 3A), meaning the underlying cause (e.g., pressure, venous hypertension) has been corrected and blood supply is sufficient.
- Infection Control: Confirm the absence of deep infection using the STONEES criteria, specifically looking for a temperature increase of \ge3^{\circ} F versus the mirror-image site on the opposite limb. Local, superficial infection must be managed via NERDS criteria (Nonhealing, Exudate, Red friable tissue, Debris, Smell).
- The 4-Week Rule: Our evidence-based benchmark is clear: a healable wound should show a 20% to 40% reduction in size by week 4. If it hasn’t met this trajectory, it is “stalled” and becomes a candidate for advanced biologics.
3. Deep Dive into Advanced Biologics: Science and Function
Understanding the “why” behind these technologies allows us to select the right tool for the right compartment of the wound.
Growth Factors
We specifically utilize Platelet-derived growth factor (PDGF), often in the form of recombinant human PDGF-BB. These molecules stimulate cellular migration and proliferation. In clinical practice, PDGF has been shown to significantly reduce healing time and improve closure rates in Stage 3 and 4 pressure injuries and diabetic foot ulcers.
Acellular Matrices and Protease Modulators
Stalled wounds are often trapped in a persistent inflammatory phase characterized by high levels of proteases, specifically matrix metalloproteinases (MMPs) and elastase. These enzymes degrade the extracellular matrix and growth factors. Protease modulating dressings rebalance this environment.
To understand this, we use the Sibbald Cube concept. We must treat the wound like a “bowl of soup”:
- The Superficial Compartment (The Surface): Managed with topical modulators and antimicrobials (NERDS).
- The Deep/Surrounding Compartment (The Sides/Bottom): Managed with systemic interventions (STONEES). Advanced matrices provide a scaffold for new tissue while neutralizing destructive enzymes on the surface.
Bioengineered Skin Substitutes (Living Skin Equivalents/LSE)
LSEs are bilaminar structures consisting of epithelium cultured on a dermal equivalent. They act as a scaffold and provide living cells that mimic a skin graft.
- Regional Practice Note: While LSEs are a gold standard in clinical literature, they are not currently available in Canada (Source Table 18). For our Canadian colleagues, we must focus on available matrices and growth factors.
4. Targeted Application: Which Wounds Benefit Most?
| Product Category | Recommended Wound Types | Clinical Goal | Specific Examples |
| Growth Factors | Stage 3 & 4 Pressure Injuries, DFUs | Stimulate cell migration/proliferation | Recombinant human PDGF-BB |
| Protease Modulators | Stalled VLUs, Stalled Healable Wounds | Neutralize MMPs and elastase | Collagen/ORC matrices |
| Skin Substitutes | Chronic DFUs, Venous Leg Ulcers | Provide living cells/scaffold | LSE (Availability varies by region) |
5. The Nurse’s Role: Implementation and Monitoring
When you are at the bedside, the success of these orders depends on your meticulous execution.
- Meticulous Preparation: Ensure the wound is debrided of all non-viable tissue and slough. Biologically active products require direct contact with a clean, viable wound bed to function.
- Contraindication Check: Verify there are no sinus tracts, excessive exudate, or active infection, as these will cause the therapy to fail.
- Cultural and Patient Advocacy: Many advanced products are derived from bovine (cow) or porcine (pig) sources. We must advocate for our patients by discussing the source of the product to ensure it aligns with their religious or cultural beliefs.
- Trajectory Tracking: Consistency is vital. Ensure you use the same measurement method (e.g., longest length x widest width at right angles) every time. Use the following formula to calculate progress:
- Percentage of Wound Healing = [(Area at Visit 1 – Area at Visit 2) / Area at Visit 1] x 100
- Patient Empowerment: Use the 4-step decision-making guide. Ask if the wound is capable of healing, select the method with the patient, investigate characteristics (pain/exudate), and consider the care setting.
6. Conclusion: The “Team Without Walls” Approach
Advanced biologics are never a “magic bullet” used in isolation. Statement 10 reminds us that these products are only effective as part of an interprofessional “team without walls.” We must prioritize patient-centered concerns, such as pain management and nutrition (utilizing the Canadian Nutritional Screening Tool), alongside high-tech interventions. Our goal is to link the patient to the right specialists at the right time.
7. Practice Pearls for the Bedside
- Foundation First: Advanced therapies will fail on an unprepared wound bed. Prioritize debridement and infection control before application.
- The 3-Degree Rule: When assessing for deep infection (STONEES), a temperature increase of \ge3^{\circ} F compared to the opposite limb is a critical indicator for systemic intervention.
- Treat the Cause: Never reach for a growth factor before addressing the cause. This means offloading for DFUs and compression for VLUs (confirmed by AHHD multiphasic signals).
- Discontinue if Stalled: If the wound does not show progress on its new trajectory after a reasonable trial, discontinue the expensive therapy and reassess for alternate diagnoses.